top of page
  • Writer's pictureKendall
    • Aug 14, 2014

Chondrial Therapeutics LLC is developing a drug for Friedreich’s Ataxia


Doctors with Chondrial Therapeutics LLC are on the verge of a human trial to test a delivery method of a protein called frataxin, which is used by each cell’s power plants—called mitochondria—to convert fat and sugar into energy. Friedreich’s Ataxia (FA) patients’ cells do not produce enough frataxin, causing the central nervous system breakdown.

After teaming up with Ron Bartek, founder of the Friedreich’s Ataxia Research Alliance, the research is on track for Phase 1 of the trials to begin in 2016. To read more about Chondrial Therapeutics LLC and their work with FA, click here.

#friedreichsataxia #clinicaltrials #treatment

21 views0 comments

Recent Posts

See All

I am a freelance columnist for Friedreich's Ataxia News. I was recently published on my column, My Darling Disability, and I wanted to share it here, too. You can either read it by following this link

I am a freelance columnist for Friedreich's Ataxia News. I was recently published on my column, My Darling Disability, and I wanted to share it here, too. You can either read it by following this link

I am a freelance columnist for Friedreich's Ataxia News. I was recently published on my column, My Darling Disability, and I wanted to share it here, too. You can either read it by following this link

bottom of page